AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06338475 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Supportive Listening (ISL)
Description: ISL sessions will be matched in terms of time and attention. Supportive therapy will be non-directive and will primarily reinforce a patient's ability to manage stressors through attentively listening and encouraging expression of thoughts and feelings, assisting the individual to gain a greater understanding of their situation and alternatives, and helping to buttress the individual's self-esteem and resilience. This will be delivered in the same manner as GET (individually) and is a common, non-directive control method in intervention research.
Study NCT05344352 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8-week daily administration
Study NCT06212622 — intervention group
Intervention type: DRUG
Intervention: Alfentanil
Description: Subcutaneous injection
Study NCT06212622 — intervention group
Intervention type: DRUG
Intervention: Oxycodone
Description: Oral solution
Study NCT06572553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab (faricimab-svoa; Vabysmo), a bispecific antibody that inhibits both VEGF-A and Ang-2, was developed by Roche/Genentech, and dual-pathway inhibition may provide stronger and longer-lasting efficacy in the treatment of retinal vascular disease relative to anti-VEGF therapy alone.
Study NCT05620654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin
Description: The starting dose for paclitaxel was 175 mg/m2, with escalation in 25 mg/m2 increments until the MTD was determined or the maximum dose level of 225 mg/m2 was reached. The target dose-limiting toxicity (DLT) rate was 25%, and the total sample size was 30 patients. HIPEC was delivered immediately following the debulking surgery using the closed technique with a target temperature of 43 ℃ for 90 minutes.
Study NCT05769452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: closed IV catheter system (BD Nexiva™)
Description: There is a high-pressure extension set and a Q-syte split septum needle-free intervention device at the tip of the catheter. It creates a closed integrated system with this apparatus, reducing the risk of catheter-related bloodstream infection.
Study NCT04985266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125Mg Tab
Description: Palbociclib Tablets, 125 mg orally once daily, beginning on Cycle 1, on Days 1-21 of each 28-day cycle.
Study NCT04985266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant injection
Description: Fulvestrant Intramuscular injections, 500 mg as two injection of 250mg fulvestrant in 5ml solution at each visit. No fulvestrant dose reductions are permitted. Administered on days 1, 15 (plus or minus 3 days), 29 (plus or minus 3 days), and every 28 (plus or minus 3 days) days thereafter.
Study NCT04985266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: As per clinical guidelines
Study NCT04985266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: As per clinical guidelines
Study NCT04985266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: As per clinical guidelines
Study NCT04985266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: As per clinical guidelines
Study NCT05755698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Awareness and Expression Therapy
Description: Each EAET session will use an educational lecture, discussion, in-class experiential exercises, and homework assignments. During sessions, participants will be encouraged to identify their stressors and experience and express their avoided or suppressed emotions, using exercises such as emotional disclosure, role playing, and the empty chair technique. Participants will be given homework assignments to complete between sessions, including expressive writing, identification of stressors and avoided emotions, and healthy communication skills practice. The planned topics of the EAET sessions include the emotions-stress-pain model, expressing and experiencing emotions (anger, sadness, hurt, etc.), letting go/forgiveness of self and others, and healthy communication, including assertiveness and intimacy.
Study NCT04831398 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melatonin
Description: A 5mg dose of melatonin spay will be delivered sublingually.
Study NCT04831398 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 sprays of diluted mint extract. This mimics the sensation and taste of the melatonin spray
Study NCT05769452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: open IV catheter (BD Insyte™ Autoguard™)
Description: BD Instaflash™ needle technology improves initial entry success by confirming vascular access through the needle noch. It has flexible wings for secure cannula fixation.
Study NCT04810351 — intervention group
Intervention type: OTHER
Intervention: observational study
Description: There is no intervention. It is an observational study
Study NCT06439758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1000 mg/day for 6 months
Study NCT06439758 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle
Description: Dietary lifestyle modifications
Study NCT05316857 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Orelabrutinib + Rifampin
Description: Orelabrutinib + Rifampin
Study NCT05316857 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Orelabrutinib + Itraconazole
Description: Orelabrutinib + Itraconazole
Study NCT04396717 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pritumumab
Description: Pritumumab IgG1 human monoclonal antibody
Study NCT05144243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet: Oral
Study NCT05144243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous Injection (SC)
Study NCT05337501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collecting data
Description: Anamnesis, clinical examination, Quantitative Sensory Testing (following DFNS, German Research Network on Neuropathic Pain, protocol), visual TOJ (Temporal Order Judgement) task
Study NCT05264805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% Bupivacaine
Description: 20ml of 0.25% Bupivacaine subcutaneous infiltration at port site wound.
Study NCT05203003 — intervention group
Intervention type: OTHER
Intervention: Assessment of MRD
Description: Bone marrow aspirate for assessment of MRD will be performed at 2 years (+/- 3 month) after randomization in patients still under treatment and in complete response.~Thereafter, bone marrow aspirate for assessment of MRD will be repeated at 3 and 4 years in patients that maintain complete response, irrespective of the randomization arm and therefore of treatment administration.
Study NCT05308654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-453
Description: Oral; Tablet
Study NCT05308654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral Tablet
Study NCT05308654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Subcutaneous Injection
Study NCT05308654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral Capsule
Study NCT04951817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 PSMA ligand
Description: For PET/CT PSMA scan, the subject will have catheter(s) placed for intravenous administration of \[68Ga\]PSMA-11. Subjects will receive a single intravenous bolus of 2-5 mCi \[68Ga\]PSMA-11 and received PET/CT scan 60 minutes later.PSMA PET-CT scan was performed on a GE Discovery MI PET/CT system.
Study NCT05273892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet + Activity + Sleep
Description: Personalized lifestyle behavior change counselling
Study NCT05273892 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet + Activity
Description: Personalized lifestyle behavior change counselling
Study NCT05234346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg 5-ALAPhosphate + SFC
Description: 2 capsules in the morning after breakfast (before 11 AM) and 1 capsule in the evening after a snack or after dinner (before 8 PM) orally with water for 21 days.
Study NCT05234346 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No Description for the intervention
Study NCT06696729 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Topical Mirabilite Application for Postoperative Gastrointestinal Patients
Description: Participants in this group will receive an external application of 500 grams of Mirabilite (sodium sulfate decahydrate) beginning on postoperative day 1. The Mirabilite will be wrapped in a double layer of gauze and placed on top of the sterile dressing over the patient's abdominal incision, with the gauze bag secured by an abdominal binder. The application will be regularly replaced when it becomes damp and hardened to maintain continuous efficacy.
Study NCT06696729 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard Postoperative Care for Gastrointestinal Patients
Description: Participants in this group will receive standard postoperative care without the application of Mirabilite or any alternative topical treatment. Their surgical sites will be kept dry and clean, with regular sterile dressing changes as part of standard care protocols.
Study NCT06700863 — intervention group
Intervention type: RADIATION
Intervention: Radiation Therapy
Description: Radiotherapy for Head and Neck Cancer Patients
Study NCT06700785 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lysine butyrate
Description: Lysine butyrate supplement. This study will compare plasma pharmacokinetic profiles of three commercially available butyrate supplements.
Study NCT06700785 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Butyrate
Description: Oral sodium butyrate supplement.
Study NCT04545814 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Maximum Tumor Diameter ≤ 2 cm = 20-24 Gy; Maximum Tumor Diameter 2.1-3.0 cm = 18 Gy; Maximum Tumor Diameter 3.1-5.0 cm = 15 Gy
Study NCT06700785 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tributyrin
Description: Oral tributyrin supplement.
Study NCT06700837 — intervention group
Intervention type: OTHER
Intervention: Impact of hypoxic burden on objective and subjective sleepiness in patients treated for Obstructive Sleep apnea
Description: To determine whether hypoxic load is a predictive marker of objective residual sleepiness measured by MCT in a treated OSAHS population.
Study NCT06700902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taking Action
Description: Participants in the experimental condition will participate in the Taking Action intervention, which will be delivered in a small group format in 5 weekly 2.5 hour videoconferencing sessions. Taking Action will be implemented using materials available on SAMHSA's website (https://www.co.ozaukee.wi.us/DocumentCenter/View/8198/Taking-Action-A-MH-Recovery-Self-Help-Ed-Program?bidId=). The process will include an overview of key recovery and wellness concepts and the development of an individualized wellness toolbox, which is a list of skills and strategies that a person already uses or would like to use to maintain or regain wellness. Then, participants will make plans for monitoring and addressing distressing mental health symptoms. Instructional techniques will include lectures, discussions, personal examples from facilitators and participants own lives to illustrate key concepts related to self-management, individual and group exercises, and voluntary action plans between meetings.
Study NCT06395584 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: White Light LED
Description: Participants will be exposed to white LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
Study NCT06395584 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Green Light LED
Description: Participants will be exposed to green LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
Study NCT06702189 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EXOPULSE MOLLII SUIT (active)
Description: Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company.~Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more. EXOPULSE Mollii suit consists of transcutaneous stimulation of several muscles by means of a feeble electric current (i.e., low frequency \~20 Hz, low-intensity 2mA), aiming to reduce pain.~This treatment method theoretical background primarily refers to the theory of gate control. Based on this theory, the stimulation of large proprioceptive fibers would inhibit the nociceptive information transmitted by small fibers.
Study NCT05166252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time out from smartphone use during meal time
Description: One parent will be instructed to install a study app. Further, he/she press a button within the App to start a time out from the smartphone at the beginning of a meal (i.e. calls and message are blocked and the parent needs to press an extra button in order to leave the app). The app instructs all other family members to turn off their phones and to put them away. Then, the parent is instructed to take a picture with their smartphone from the smartphone-free family meal table . The time-out is over as soon as the parent presses the stop button.
Study NCT05166252 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control condition
Description: The same as the experimental condition but without a timeout from smartphone use.
Study NCT05769673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of dental implant
Description: Placement of a dental implant on the edentulous ridge
Study NCT05769673 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of dental implant
Description: Placement of a dental implant on the edentulous ridge
Study NCT05769673 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of stock healing abutment
Description: Placement of stock healing abutment after implant has been placed on the edentulous ridge
Study NCT05769673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of customized CAD/CAM healing abutment
Description: Placement of customized CAD/CAM healing abutment after implant has been placed on the edentulous ridge
Study NCT06460701 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: m-CIMT without Kinesio taping
Description: Baseline treatment m-CIMT will be applied includeing ROM with a sling, e.g shoulder flexion, extension, abduction, and rotation. The elbow's flexion and extension, Forearm supination is the extension of the wrist and fingers. Functional Training Using a tiny toy ball, practice tossing and catching it from various angles. Play with modeling clay, constructing towers of the toy bricks using LEGOs,Using crayons, ripping a piece of paper towel,Grasping biscuits, Using a spoon, utilizing a glass to drink, comb hair, brush teeth,Using a bubble blower,With a toy in hand, putting cap, putting lotion.stretching to shoulder's extensors, adductor, and internal rotators ,wrist and elbow flexors. strengthening exercises e.g a ball above head position in various directions,Using paper adhered to the window or wall at varying heights for drawing. The session will go for one hour.
Study NCT06460701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: m-CIMT along with kinesiotaping
Description: Modified constraint-induced movement therapy along with kinesiotaping will be applied. m-CIMT protocol is baseline treatment and it is is same as in the other group.~This group also participated additionally in a kinesio taping program, which utilize KT with the goal of enhancing middle and lower trapezius function to increase stability in the scapula on the afflicted side. During the application of the tape, the shoulders were kept in a low and backward posture, and the scapular alignment was manually maintained. KT was administered at the acromion and positioned medially at the spinous processes (T2-T3 for the middle trapezius and T12 for the lower trapezius). For eight weeks in a row, there will be three sessions every week
Study NCT05041166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized [13C] Pyruvate
Description: Will be injected at a dosage of 0.43 ± 0.05 mL/kg body weight
Study NCT05169879 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronal flaring
Description: early coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone
Study NCT05169879 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non coronal flaring
Description: No coronal flaring will be performed
Study NCT06317805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic treprostinil sodium + Standard of Care (Double Oral)
Description: Treprostinil (prostacyclin analogue) solution for continuous subcutaneous (SC) or intravenous (IV) infusion (1 mg/ml; 2.5 mg/ml; 5 mg/ml; 10 mg/ml in 10 mL glass vial) will be administered by an infusion pump system and up-titrated to ≥40 ng/kg/min or to the maximum tolerated dose within 24 weeks. Further up-titration shall be performed until trial completion according to the discretion of the investigator.
Study NCT06317805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care - Double Oral
Description: All patients will receive standard of care double oral background treatment consisting of one Phosphodiesterase type 5 inhibitor (i.e., tadalafil or sildenafil) and one Endothelin Receptor Antagonist (i.e. ambrisentan, bosentan or macitentan)
Study NCT06317805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care - Double Oral
Description: All patients will receive standard of care double oral background treatment consisting of one Phosphodiesterase type 5 inhibitor (i.e., tadalafil or sildenafil) and one Endothelin Receptor Antagonist (i.e. ambrisentan, bosentan or macitentan)
Study NCT01070290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197
Description: 120 mg capsule administered twice daily
Study NCT01070290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin, capecitabine or irinotecan
Description: Investigator's choice or oxaliplatin, capecitabine or irinotecan
Study NCT06531759 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fentanyl
Description: Fentanyl soaked nasal packs.
Study NCT06431620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Thyroid Stimulating Hormone
Description: recombinant human thyrotropin (rhTSH) injection: 0.9mg/1.0mL/piece; intramuscular injection; once a day for two consecutive days.
Study NCT06288815 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral fluid
Description: Postoperation~* Off IV fluid immediately postoperative~* Allow patients drink oral fluid as protocol for 24hr
Study NCT06288815 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IV fluid
Description: Postoperation~* IV fluid replacement as protocol for 24hr~* Allow patients drink oral fluid as usual
Study NCT06171867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PNEUMACRIT
Description: Monitoring of breathing
Study NCT06043362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0 mg nicotine pouch
Description: Oral nicotine pouches that contain 0 mg of nicotine
Study NCT06043362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 mg nicotine pouch
Description: Oral nicotine pouches that contain 3 mg of nicotine
Study NCT06043362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6 mg nicotine pouch
Description: Oral nicotine pouches that contain 6 mg of nicotine
Study NCT06043362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smooth nicotine pouch
Description: Non-flavored nicotine pouches that are characterized as smooth.
Study NCT06043362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wintergreen nicotine pouch
Description: Menthol flavored nicotine pouches that are characterized as wintergreen.
Study NCT06057415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAPTOS (Handling Adapted to Postnatal age with Tactile-kinaesthetic and Oral sensorimotor Stimulation
Description: Tactile-kinaesthetic and Oral sensorimotor Stimulation
Study NCT04908813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX22
Description: IV Q3W D1
Study NCT04908813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: IV Q3W D1
Study NCT04908813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: IV Q3W D1
Study NCT04908813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: IV Q3W D1
Study NCT04908813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV Q3W D1
Study NCT06571292 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intensive training with robotic exoskeleton for upper limbs
Description: Both groups will be trained with robotic exoskeleton for upper limbs and task specific training.